We have previously shown that the clinically relevant polyamine analog N 1 ,N 11 -diethylnorspermine (DENSPM) causes rapid apoptosis in human melanoma SK-MEL-28 cells via a series of events that include mitochondrial release of cytochrome c and activation of the caspase cascade. Upstream to these events, DENSPM downregulates polyamine biosynthesis and potently upregulates polyamine catabolism at the level of spermidine/spermine N 1 -acetyltransferase (SSAT). In searching for downstream effectors that either contribute to or abrogate the apoptotic response, we observed that DENSPM treatment of SK-MEL-28 cells for 30 h led to cytosolic release of Smac/Diablo, a mitochondrial protein known to bind and inhibit the function of inhibitor of apoptosis proteins (IAPs). Subsequently, we found that DENSPM markedly lowered survivin and ML-IAP protein (but not XIAP) levels by 18 h via an apparently Smac/Diablo-independent pathway. Proteasome inhibitors fully prevented survivin and ML-IAP protein loss as well as apoptosis, suggesting that the proteasome-mediated degradation of survivin and ML-IAP is causally linked to the cellular outcome. We also observed that structural analogs of DENSPM which differentially induced SSAT and apoptosis lowered survivin and ML-IAP levels in a manner that correlated with enzyme activity. The linkage between IAPs and SSAT was more directly established by the finding that selective prevention of SSAT induction by small interfering RNA prevented survivin and ML-IAP loss as well as apoptosis during DENSPM treatment. Among the melanoma cell lines (SK-MEL-28, MALME-3M, A375 and LOX), survivin degradation correlated temporally with the onset of DENSPM induced apoptosis or growth inhibition. By contrast, ML-IAP degradation occurred only during rapid apoptosis seen in SK-MEL-28 cells. These data suggest a sequence of events whereby DENSPM induction of SSAT leads to loss of IAP proteins and a more fulminate apoptotic response. The findings implicate survivin and ML-IAP as important determinants of polyamine analog drug action in melanoma cells.
Introduction
The balance between apoptotic and antiapoptotic proteins plays an important role in determining the response of cancer cells to chemotherapeutic agents. It is now well documented that signals funneling toward caspase activation and apoptosis can be modulated by a family of proteins called inhibitors of apoptosis proteins (IAPs) (Salvesen and Duckett, 2002) . Members of the IAP family have one or more baculoviral IAP repeats (BIR), which are crucial for their antiapoptotic activity and interaction with caspases (Hinds et al., 1999) . The seven human IAP family members are c-IAP1, c-IAP2 (Rothe et al., 1995) , XIAP (Duckett et al., 1996) , NAIP (Liston et al., 1996) , survivin (Ambrosini et al., 1997) , apollon (Chen et al., 1999) and ML-IAP (also known as livin) (Vucic et al., 2000; Kasof and Gomes, 2001) . IAPs have specific expression patterns and some of them (i.e. c-IAP1, c-IAP2, survivin and ML-IAP) are associated with cancer (LaCasse et al., 1998; Salvesen and Duckett, 2002) . Survivin is highly expressed in a variety of human tumors and in fetal tissues, but not in differentiated adult tissues (Ambrosini et al., 1997) . Importantly, survivin has also been shown to suppress apoptosis in the G 2 /M phase by inhibiting activation of caspase-3 and -7 (Shin et al., 2001) . Like survivin, expression of ML-IAP is increased in transformed cells and embryonic tissues, and it tends to be preferentially overexpressed in human melanomas (Vucic et al., 2000) . The antiapoptotic activity of ML-IAP is exerted via binding and inhibiting caspase-3 and -9 through its BIR domain (Vucic et al., 2000) . Owing to their specific and unique expression patterns, both survivin and ML-IAP have been recognized as attractive targets for cancer therapy. -diethylnorspermine (DENSPM) is a polyamine analog, which has undergone clinical evaluation against solid tumors including malignant melanoma (Creaven et al., 1997; Streiff and Bender, 2001; Hahm et al., 2002) . Such analogs typically downregulate the polyamine biosynthetic enzymes ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) and potently upregulate the catabolic enzyme spermidine/spermine N 1 -acetyltransferase (SSAT) (Porter and Bergeron, 1988; Porter et al., 1991) , culminating in polyamine pool depletion and inhibition of cell growth. Previously, we showed that DENSPM treatment of a panel of human melanoma cell lines revealed a strong correlation between induction of SSAT, activity and growth inhibition (Shappell et al., 1992) . In characterizing one of the most sensitive melanoma lines, SK-MEL-28, we found that DENSPM-induced apoptosis is triggered by its ability to stimulate polyamine catabolism via SSAT which is followed by mitochondrial apoptotic signaling and caspase activation . Thus, although initiated by SSAT induction, DENSPM-mediated apoptosis is ultimately dependent on multiple downstream effectors that together or individually could critically determine overall sensitivity to polyamine analog. Based on the IAP expression patterns in melanoma tumor cells and their known ability to interfere with caspase activation (Ambrosini et al., 1997; Vucic et al., 2000) , we investigated the possible role of these interesting molecules in polyamine analog-induced apoptosis in SK-MEL-28 cells. A further goal was to determine whether IAP responses might represent a determinant of drug action for this class of anticancer agents.
Results

Cell growth and apoptosis
We have previously reported the kinetics of various events believed to contribute to cell growth and apoptosis of SK-MEL-28 cells treated with 10 mm DENSPM . Briefly, maximum induction of SSAT and polyamine depletion take place by 16 h of treatment. Cell growth is inhibited by 24 h of treatment, cytochrome c release and caspase-3 activation take place at 30-36 h and apoptosis begins at 36 h. According to positive annexin V staining, 50% of the cell population is apoptotic by 48 h. In data described below, growth and apoptotic effects in DENSPMtreated SK-MEL-28 cells are shown from 0 to 96 h for comparison with other melanoma cell lines in Figure 6 .
Smac/Diablo release by DENSPM
In similarity to cytochrome c, the mitochondrial protein Smac/Diablo can be released into the cytosol through mitochondrial damage by apoptotic stimuli (van Loo et al., 2002) . Having previously reported release of cytochrome c with DENSPM treatment , we next examined whether Smac/Diablo was also released. As shown in Figure 1 , Smac/Diablo was mainly located in the mitochondria of untreated cells. Following DENSPM treatment, the protein was released in a pattern similar to cytochrome c (Figure 1) . Specifically, the protein shifted from the mitochondria into the cytosol beginning at 24 h and rapidly accumulated to significant levels by 30 h of treatment.
Selective inhibition of IAPs by DENSPM treatment
As Smac/Diablo is known to exert its proapoptotic effect by interfering with IAP function (Du et al., 2000; Verhagen et al., 2000) , we next examined expression levels of relevant IAPs during DENSPM-induced apoptosis. Among the IAP family members, survivin and ML-IAP (also known as livin) were chosen because of their common association with caspase-3 and -9 and their elevated expression in cancer cell lines, particularly in those of melanoma origin (Tamm et al., 1998; Vucic et al., 2000; Kasof and Gomes, 2001) . As shown in Figure 2a , there was a time-dependent decrease in survivin protein levels that was first apparent at 18 h and reached a maximum reduction (480%) by 24 h of DENSPM treatment. As in the case of survivin, ML-IAP protein levels were significantly reduced by 24 h of treatment and below detectable limits by 36 h (Figure 2a ). In contrast, DENSPM treatment did not affect XIAP expression (Figure 2a) , which is also known to inhibit caspase (Deveraux et al., 1997) . Unlike DENSPM, the natural polyamine, spermine (Spm, at 10 mm) failed to affect any of the three IAP proteins during treatments for up to 36 h (Figure 2a ).
Proteasome-mediated degradation of survivin and ML-IAP by DENSPM As shown in Figure 2b , the survivin RNA levels did not change with DENSPM treatment suggesting that the loss of survivin protein (Figure 2a ) occurs via posttranscriptional mechanisms such as increased protein degradation. Consistent with this hypothesis, preincubation of SK-MEL-28 cells with the specific 26S proteasome inhibitor MG-132 for 1 h prior to DENSPM treatment prevented survivin and ML-IAP loss in a dose-dependent manner (Figure 3a) . Similar protection from degradation was also obtained using Clasto-lactocystin b-lactone at 1 and 10 mm (data not shown). Using annexin V to stain cells treated with DENSPM plus MG-132 revealed that, in addition to blocking IAP degradation, the inhibitor prevented DENSPM-induced apoptosis in a dose-dependent manner (Figure 3b ). Although MG-132 is capable of preventing proteasomal degradation of other proteins, the data suggest a causal relation between DENSPMinduced degradation of survivin and/or ML-IAP and apoptosis. 
Effect of SSAT induction on IAP expression
We next examined whether SSAT induction is related to IAP degradation. For this purpose, we relied initially on DENSPM analogs that similarly downregulate polyamine biosynthesis and deplete polyamine pools but differentially induced SSAT activity (Kramer et al., 1999) . The analogs were previously used to link SSAT induction with caspase activation and apoptosis in SK-MEL-28 cells . Thus, SK-MEL-28 cells were treated with each of the four analogs for 36 h and examined for relative effects on IAP levels. As shown in Figure 4 , two analogs ) that induced relatively low levels of SSAT (26-and 149-fold, respectively) failed to cause survivin and ML-IAP degradation at 36 h. DE-343 induced intermediate levels of SSAT (270-fold) and reduced both survivin and ML-IAP levels. The most potent SSAT inducer (DENSPM, 912-fold) exerted the greatest inhibitory effect on both IAP proteins, reducing levels by B80%. XIAP levels were unaffected by any of the analogs (Figure 4 ). By comparison, spermine did not cause IAP protein degradation ( Figure 2a ) and was also a very low SSAT inducer (Bsevenfold) (data not shown). These data suggest that specific reduction of IAPs, survivin and ML-IAP, is among the downstream proapoptotic events triggered by analog stimulation of polyamine catabolism.
Prevention of SSAT induction by siRNA
To more definitively evaluate the above correlation between SSAT induction and IAP loss, we designed an siRNA targeting the coding region of the SSAT mRNA (siSSAT200, Chen et al., submitted Molecular Pharm., the use of small interfering RNA to define the metabolic and apoptotic consequences of spermidine/spermine N 1 -acetyltransferase induction). As shown in Figure 5 , addition of siSSAT200 (83 nm) blocked DENSPMinduced SSAT protein by 490%. Significantly, degradation of survivin and ML-IAP, activation of caspase-3 and apoptosis by DENSPM were firmly blocked by siSSAT200. These data provide direct evidence that degradation of certain IAPs is among the downstream proapoptotic responses that emanate from DENSPM induction of SSAT. It is important to note that in the absence or presence of siSSAT, DENSPM was accumulated to similar intracellular levels (data not shown). These data rule out the possibility that the analog had directly or indirectly stimulated IAP degradation through actions other than SSAT induction.
Survivin degradation with DENSPM sensitivity in other melanoma lines
We next examined the generality of these causal linkages by comparing effects on growth kinetics and apoptosis with survivin protein levels among a panel of DENSPM-treated melanoma cells (Figure 6 ). In SK-MEL-28 cells, 10 mm DENSPM potently induced SSAT activity by 16 h , decreased survivin levels by 24 h, halted cell growth by 24 h and significantly induced apoptosis between 24 and 48 h. In MALME-3M cells, DENSPM induced SSAT activity (Table 1 ) and inhibited cell growth by 24 h (Figure 6 ). However, survivin was not decreased until 48 h and apoptosis was not apparent until 72-96 h. In two other human melanoma lines, A375 and LOX, DENSPM induced SSAT activity very weakly (Table 1) . These cells were not growth inhibited until 48 h and this was followed by a relatively minor apoptotic response at 72-96 h (Figure 6 ). Survivin levels remained relatively unchanged until 72 h, a response that may reflect the inhibition of cell growth. In addition, the greatest reduction in polyamine pools and accumulation of acetylated products were observed in SK-MEL-28 and MALME-3M cells in which DENSPM induced highest SSAT (Table 1) . Although exaggerated in SK-MEL-28 cells, DENSPM accumulation was similar for the MALME-3M, A375 and LOX cells (Table 1) and, therefore could not account for the observed differences in cellular response. Thus, from four melanoma lines, DENSPM-mediated degradation of survivin correlated with upstream induction of SSAT and with downstream apoptotic responses. Interestingly, ML-IAP was only decreased in SK-MEL-28 cells and it may therefore, contribute to the rapidity of their response to DENSPM. For comparison, a normal human fibroblast line derived from the MALME-3M patient contained no detectable levels of survivin, ML-IAP or XIAP proteins (data not shown). These same fibroblasts were for 24 h for enzyme activity assay, or 36 h for Western blot to determine protein levels of survivin, ML-IAP and XIAP, or 48 h for annexin V assay. These analogs accumulate to similar levels in cells and similarly downregulate biosynthetic enzymes; they differ in their abilities to induce SSAT (Kramer et al., 1999) . Data represent three separate experiments previously shown to induce very little SSAT and to be remarkably insensitive to DENSPM treatment (Shappell et al., 1992) .
DISCUSSION
Our ongoing interest has been to identify the cell cycle (Kramer et al., 1999 ) and apoptotic pathways ) that are responsive to polyamine analog-induced perturbations in polyamine pool homeostasis and to define their role in determining cellular outcomes. The larger goal is to examine how these responses might be exploited as therapeutic markers and/or targets. Here, we examined the role of selected IAPs on caspase-dependent apoptosis and their relation to SSAT induction in melanoma cells.
Our lead finding in this effort was that the proapoptotic mitochondrial protein Smac/Diablo is released from mitochondria prior to apoptosis in DENSPMtreated SK-MEL-28 cells (Figure 1) . Cytosolic Smac/ Diablo is known to bind to IAPs and, thus, abrogate their ability to interfere with caspases and apoptosis (Du et al., 2000; Verhagen et al., 2000) . Since Smac/Diablo and cytochrome c release occur prior to caspase-9 and -3 activation and apoptosis in DENSPM-treated SK-MEL-28 cells, we hypothesized that caspase activation may be modulated by IAPs. We chose to investigate survivin and ML-IAP because both are commonly overexpressed in melanoma cell lines (Tamm et al., 1998; Vucic et al., 2000) and because they Our results clearly show that DENSPM treatment produces a loss in survivin protein in SK-MEL-28 cells, suggesting a role for this IAP in the subsequent apoptotic response. Survivin is a recently identified member of the IAP family and is known to inhibit caspase activity and apoptosis triggered by Fas, Bax, caspases and various anticancer agents (Tamm et al., 1998) . Overexpression of survivin is associated with loss of apoptosis (Tanaka et al., 2000) and a reduction of survivin by antisense oligonucleotides induces apoptosis and sensitizes cancer cells to drug treatment (Olie et al., 2000) . We found that survivin loss occurs posttranscriptionally and that it is proteasome-dependent as has been reported by others. For example, Zhao et al. (2000) overexpressed survivin in human embryonal kidney 293 cells and observed that degradation of survivin was mediated by the ubiquitin-dependent proteasome regulatory pathway. We note, however, that while DENSPM induced proteasome degradation of certain IAPs, ubiquinated species were not detected (data not shown).
In examining other IAPs, we found that SK-MEL-28 cells contain high ML-IAP protein levels and, as with survivin, proteasome-dependent degradation of ML-IAP occurred prior to DENSPM-induced apoptosis. Vucic et al. (2000) reported that transiently overexpressed ML-IAP rendered human breast carcinoma MCF-7 cells resistant to apoptosis induced by death receptors and the chemotherapeutic drug adriamycin by inhibiting caspase-3 and -9 activation (Vucic et al., 2000) . The finding that MG-132 interference with ML-IAP and survivin degradation abrogates apoptosis (Figure 3 ) further confirms that these IAPs are antiapoptotic in function and provides direct evidence that they are involved in DENSPM action.
As an indication of the specificity of DENSPM targeting of survivin and ML-IAP in SK-MEL-28 cells, we note that another IAP, XIAP was unaffected during analog treatment. This is a somewhat unexpected observation, since XIAP is the most potent inhibitor of cytochrome c-induced caspase-9 processing and of caspase-3 and -7 activity (Deveraux et al., 1998) and since its modeled structure most closely resembles ML-IAP (Vucic et al., 2000) . The lack of XIAP degradation excludes the possibility that DENSPM-induced loss of survivin and ML-IAP was due to stimulation of generalized proteasomal degradation. We did not examine analog effects on cIAP-1 and cIAP-2 levels due to their close similarity in function to XIAP (Holcik and Korneluk, 2001; Salvesen and Duckett, 2002) .
As Smac/Diablo has been shown to interact physically with ML-IAP and abolish the antiapoptotic function of ML-IAP (Vucic et al., 2002) , our data suggest a model in which DENSPM induction of SSAT leads to the mitochondrial release of Smac/Diablo, which, in turn, interferes with IAP antiapoptotic activity and accelerates apoptosis. One inconsistency in this model, however, is that the IAPs disappear (24 h) before Smac/ Diablo is released (30 h) suggesting that accelerated apoptosis is due to a Smac/Diablo-independent pathway that causes IAP degradation.
Several lines of evidence indicate that the degradation of survivin and ML-IAP by polyamine analogs is initiated by the massive induction of SSAT and/or the related changes in polyamine pool dynamics, polyamine function (i.e. due to acetylation) and/or oxidative events emanating from analog induction of polyamine-directed oxidases (Vujcic et al., 2002 . Previously, we reported that induction of SSAT and related oxidative events are directly linked to cytochrome c release, caspase-3 activation and apoptosis induced by DENSPM . Here, we show that differential induction of SSAT by a panel of DENSPMrelated analogs correlates with differential degradation of survivin and ML-IAP and that the intensity of the latter corresponds with the rapidity and extent of apoptosis. More direct evidence for these linkages was provided by siRNA experiments in which we observed that selective interference of SSAT induction prevented the loss of survivin and ML-IAP as well as apoptosis. The finding unambiguously links IAPs effects to upstream SSAT induction and to downstream apoptotic events. These data are unique for two reasons. They relate DENSPM to proteasome degradation of a protein that is not involved in polyamine metabolism or transport and they do so specifically via induction of SSAT (as discussed below).
In comparing the survivin loss and apoptosis in four DENSPM-treated melanoma lines, we found a strong time-dependent correlation between the degree of survivin degradation and the apoptotic responses. The most rapid loss of survivin occurred in SK-MEL-28 cells, followed by MALME-3M cells where survivin loss clearly preceded onset of apoptosis. Significantly, these were also the two lines that induced the highest levels of SSAT during DENSPM treatment. The fact that MALME-3M cells did not undergo apoptosis as rapidly as SK-MEL-28 cells may be because survivin was not downregulated as rapidly and/or because ML-IAP was not degraded at all in MALME-3M cells. In the two lines with the lowest SSAT induction (A375 and LOX), decreases in survivin occurred much later and was accompanied by a reduction in growth rate as opposed to apoptosis. It seems likely that the decline in survivin seen in these cells may actually be secondary to growth inhibition, since Suzuki et al. (2000) reported that survivin is only expressed in proliferating cells, and is degraded once cells become growth inhibited.
These cell line data implicate IAPs as important determinants of drug action for polyamine analogs. Owing to the high levels of survivin in melanoma, this novel molecule may represent a determinant of tumor sensitivity to analogs in vivo and, thus, serve as a potential prognostic indicator. Unlike survivin, ML-IAP was only degraded by DENSPM in the cell line that undergoes rapid apoptosis (SK-MEL-28). Survivin has been implicated in preventing apoptosis and growth inhibition (Reed and Bischoff, 2000) , while ML-IAP seems to be more involved in preventing rapid apoptosis. We have recently found that DENSPM induction of SSAT leads to an activation of mitogen-activated protein kinase (MAPK) pathways, which seems to play a survival function by modulating apoptosis (Chen et al., submitted, the role of MAP kinase activation in determining cellular outcomes in polyamine analogtreated human melanoma cells). More particularly, DENSPM activation of MAPK delays apoptosis in melanoma cells containing wild-type p53, such as MALME-3M cells, by augmenting the p21 WAF1/CIP1 response and sustaining G 1 arrest. In cells containing mutated p53, such as SK-MEL-28 cells, there is no G 1 arrest and apoptosis is not delayed.
Merging these present findings with those of a prior publication gives rise to the following sequence of events in DENSPM-treated SK-MEL-28 cells (Figure 7) . DENSPM activates polyamine homeostatic mechanisms leading to downregulation of key biosynthetic enzymes and potent upregulation of SSAT. The latter results in rapid depletion of polyamine pools, possible interference with polyamine function (due to acetylation) and/or to liberation of oxidative products via SSAT-coupled oxidases. One or more of these events then initiate apoptotic signaling. Downstream proapoptotic effectors include release of cytochrome c and Smac/ Diablo from mitochondria, loss of survivin and ML-IAP levels and activation of caspase-9 and -3. In the absence of the moderating influences of survivin and ML-IAP, activated caspases mediate rapid apoptosis. We have also established that SSAT induction triggers IAP degradation and that this aligns with sensitivity of melanoma lines to DENSPM. These data further define the mode of analog action and support the more general realization that survivin and ML-IAP represent important therapeutic targets (Salvesen and Duckett, 2002) .
Materials and methods
Materials
The polyamine analog DENSPM was generously provided by Parke Davis (Ann Arbor, MI, USA) and the DENSPM analogs N 1 ,N 14 -diethylhomospermine 3, 7, 12, -443) Cell culture SK-MEL-28, MALME-3M and LOX human melanoma cells (ATCC, Rockville, MD, USA) were maintained in a 5% CO 2 -humidified incubator as monolayer cultures in RPMI 1640 supplemented with 10% Nu-Serum (Collaborative Research Products, Bedford, MA, USA). A375 human melanoma cells (ATCC) were maintained in DMEM Plus medium supplemented with 10% fetal bovine serum (Life Technologies, Gaithersburg, MD, USA). The normal human fibroblast cells (ATCC) were grown in DMEM plus medium supplemented with 15% fetal bovine serum. All culture medium was supplemented with 1 mm aminoguanidine as an inhibitor of copper-dependent bovine serum amine oxidase, to prevent oxidation of extracellular polyamines to toxic products.
Polyamine pools and enzyme activity
Intracellular polyamines and polyamine analogs were analysed by high-performance liquid chromatography (HPLC) as previously described . SSAT activity was performed as previously described (Porter et al., 1991) .
Western analysis
Cells were treated with 10 mm DENSPM or other agents for various times. Cells were harvested and total lysates (40 mg protein/lane) were run on 7.5-15% SDS-PAGE gels, followed by transfer to PVDF membrane and immunoblotted with Figure 7 Diagram of DENSPM effects on polyamine metabolism and apoptotic pathways. DENSPM downregulates polyamine biosynthesis and potently upregulates polyamine catabolism. Induction of SSAT leads to loss of survivin and ML-IAP via an apparent Smac/Diablo-independent pathway that culminates in proteasomal degradation. In the absence of IAPs, interference with caspase-3 activation is diminished (dotted line) and apoptosis proceeds rapidly in SK-MEL-28 cells. The nature of the SSATdependent initiating events (?) remains to be determined but could involve rapid polyamine depletion, loss of polyamine function due to acetylation and/or release of reactive products via SSATcoupled oxidases . Bold text and arrows denote currently defined events, while regular text and arrows denote previously defined events specific antibodies. Detection was performed with ECL from Amersham Pharmacia Biotech. (Arlington Heights, IL, USA). Protein was determined by the standard Biorad assay and bactin (Sigma, St Louis, MO, USA) was used to equalize for variations in loading.
Northern analysis
Total RNA was isolated using the RNeasy minikit (Qiagen, Valencia, CA, USA) and Northern blot analysis of survivin mRNA from untreated and 10 mm DENSPM-treated cells was conducted as reported previously (Fogel-Petrovic et al., 1996) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (Clontech Laboratories, Inc., Palo Alto, CA, USA) was used to evaluate loading.
Separation of mitochondria and cytosol
Cells incubated in the presence or absence of 10 mm DENSPM for different periods of time were harvested for separation of mitochondria and cytosol according to the method reported by Yang et al. (1997) .
Apoptosis assay
Apoptosis was analysed by annexin V/FITC staining using a kit obtained from R&D Systems (Minneapolis, MN, USA). Briefly, cells were harvested and resuspended in 1 Â binding buffer at a concentration of 4 Â 10 5 cells/100 ml. For each test, 4 Â 10 5 cells were incubated with propidium iodide (PI) (5 mg/ ml) and annexin V/FITC (0.25 mg/ml) in the dark for 15 min at room temperature. After incubation, 400 ml 1 Â binding buffer was added to stop the reaction and the tube was moved to ice. Within an hour, samples were measured by a Becton Dickinson FACScan (Flow Cytometry Facility, Roswell Park Cancer Institute). Data were analysed using the Winlist program (Verity House, Topsham, ME, USA).
Transfection of SK-MEL-28 cells with siRNA
Small interfering RNAs targeting SSAT (siSSATs) were synthesized by Xeragon Inc. (Huntsville, AL, USA). More specifically, siSSAT200 targeted nucleotides 200-218 from the start codon of SSAT mRNA (sense: 5 0 -GGA CAC AGC AUU GUU GGU U-3 0 ; antisense: 5 0 -AAC CAA CAA UGC UGU GUC C-3 0 ). For each 60-mm culture dish of cells, 15 ml of the 20 mm stock siSSAT200 duplex was mixed with 300 ml of Opti-MEM medium (Invitrogen, Grand island, NY, USA). This mixture was gently added to a solution containing 15 ml of Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) in 300 ml of Opti-MEM. The solution was incubated for 20 min at room temperature and gently overlaid onto 90% confluent cultures of SK-MEL-28 cells in 3 ml medium. The final concentration of siSSAT200 is 83 nm. After 24 h incubation, cells were treated with 10 mm DENSPM for another 36 h and harvested for Western blot analysis. 
